{
    "nct_id": "NCT05162755",
    "official_title": "A Phase 1a/1b, Open-label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Anti-neoplastic Activity of S095029 (Anti-NKG2A) as Monotherapy and in Combination With Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triplet Combinations of S095029 and Sym021 and an Anti-HER2 mAb or Anti-EGFR mAbs (Futuximab/Modotuximab) in Patients With Metastatic Gastric or Colorectal Cancers",
    "inclusion_criteria": "* Histologically or cytologically confirmed unresectable, locally advanced or metastatic solid tumor malignancies\n* Patients with a malignancy not amenable to surgical intervention\n* Patients with measurable disease and progression radiologically assessed\n* Patients with disease progression after treatment with available standard of care therapies that are known to confer clinical benefit or who are intolerant to treatment.\n* Patients with available archived tumor biopsy specimens or agree to mandatory biopsy\n* Estimated life expectancy â‰¥ 12 weeks\n* Adequate haematological function\n* Adequate renal function\n* Adequate hepatic function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnant and lactating women\n* Major surgery within 4 weeks prior to the first IMP administration or not recovered from the surgery\n* Patients with serious/active/uncontrolled infection or infection requiring parenteral antibiotics, within 2 weeks prior to first IMP administration\n* Active Hepatitis B Virus infection\n* Carriers of HIV antibodies\n* Patients with active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration\n* History of organ transplantation\n* History of gastrointestinal perforation, or intra-abdominal abscess within 28 days of inclusion\n* History of cirrhosis\n* History of pulmonary fibrosis or relevant uncontrolled chronic pulmonary condition\n* Treatment with systemic immunosuppressive therapy\n* Active autoimmune disease\n* Administration of a live vaccine within 28 days prior to inclusion",
    "miscellaneous_criteria": "Dose escalation part:"
}